(S)-(3,4-Dichloro-phenyl)-((2S,5S)-5-methyl-pyrrolidin-2-yl)-methanol | 751472-70-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-(3,4-Dichloro-phenyl)-((2S,5S)-5-methyl-pyrrolidin-2-yl)-methanol
• 英文别名: (S)-(3,4-dichlorophenyl)-[(2S,5S)-5-methylpyrrolidin-2-yl]methanol
• CAS: 751472-70-5
• 化学式: C₁₂H₁₅Cl₂NO
• 分子量: 260.163
• InChiKey: LNHGSNRHFIRUKQ-QILRFPOHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  三光气 、 4-(methylamino-t-butylcarbonyl)aniline 、 (S)-(3,4-Dichloro-phenyl)-((2S,5S)-5-methyl-pyrrolidin-2-yl)-methanol 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (2S,5S)-2-[(S)-(3,4-Dichloro-phenyl)-hydroxy-methyl]-5-methyl-pyrrolidine-1-carboxylic acid {4-[(2,2-dimethyl-propionylamino)-methyl]-phenyl}-amide
  参考文献：
  名称：

  Discovery and initial structure–Activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists

  摘要：

  Thrombin is the most potent agonist of platelet activation, and its effects are predominantly mediated by platelet thrombin receptors. Therefore, antagonists of the thrombin receptor have potential utility for the treatment of thrombotic disorders. Screening of combinatorial libraries revealed 2 to be a potent antagonist of the thrombin receptor. Modifications of this structure produced 11k, which inhibits thrombin receptor stimulated secretion and aggregation of platelets. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00538-8
• 作为产物：
  描述：

  1,1-Dimethylethyl (2S)-2-[(methoxymethylamino)carbonyl]-5-methyl-1-pyrrolidinecarboxylate 在 盐酸 、 sodium tetrahydroborate 、 正丁基锂 作用下， 以 甲醇 、 乙醚 、 乙酸乙酯 为溶剂， 生成 (S)-(3,4-Dichloro-phenyl)-((2S,5S)-5-methyl-pyrrolidin-2-yl)-methanol
  参考文献：
  名称：

  Discovery and initial structure–Activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists

  摘要：

  Thrombin is the most potent agonist of platelet activation, and its effects are predominantly mediated by platelet thrombin receptors. Therefore, antagonists of the thrombin receptor have potential utility for the treatment of thrombotic disorders. Screening of combinatorial libraries revealed 2 to be a potent antagonist of the thrombin receptor. Modifications of this structure produced 11k, which inhibits thrombin receptor stimulated secretion and aggregation of platelets. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00538-8

文献信息

• [EN] BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA<br/>[FR] AMINES HÉTÉROCYCLIQUES BÊTA-HYDROXY ET LEUR UTILISATION DANS LE TRAITEMENT DE L'HYPERGLYCÉMIE
  申请人：ATROGI AB

  公开号：WO2019053425A1

  公开（公告）日：2019-03-21

  There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, ring A, m and n have meanings as provided in the description.

  在此提供了一个式子(I)的化合物或其药用可接受的盐，其中X、R1、环A、m和n的含义如描述中所提供。
• BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA
  申请人：Atrogi AB

  公开号：EP3681862A1

  公开（公告）日：2020-07-22
• Discovery and initial structure–Activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists
  作者：James C Barrow、Philippe G Nantermet、Harold G Selnick、Kristen L Glass、Phung L Ngo、Mary Beth Young、Janetta M Pellicore、Michael J Breslin、John H Hutchinson、Roger M Freidinger、Cindra Condra、Jerzy Karczewski、Rodney A Bednar、Stanley L Gaul、Andrew Stern、Robert Gould、Thomas M Connolly

  DOI：10.1016/s0960-894x(01)00538-8

  日期：2001.10

  Thrombin is the most potent agonist of platelet activation, and its effects are predominantly mediated by platelet thrombin receptors. Therefore, antagonists of the thrombin receptor have potential utility for the treatment of thrombotic disorders. Screening of combinatorial libraries revealed 2 to be a potent antagonist of the thrombin receptor. Modifications of this structure produced 11k, which inhibits thrombin receptor stimulated secretion and aggregation of platelets. (C) 2001 Elsevier Science Ltd. All rights reserved.